Article Text

Download PDFPDF

P254 Feasibility of ultrashort echo time (ute) mri to evaluate the effect of lumacaftor/ivacaftor therapy in children with cystic fibrosis (cf) homozygous for f508del
Free

Abstract

S Nagle reports personal consulting fees from Vertex Pharmaceuticals during the conduct of the study; non-financial support from GE Healthcare (institution/department support).

AS Brody reports personal fees from Vertex Pharmaceuticals during the conduct of the study.

J Woods reports personal consulting fees from Vertex Pharmaceuticals during the conduct of the study.

KM Johnson reports personal consulting fees Vertex Pharmaceuticals during the conduct of the study.

L Wang, G Marigowda, D Waltz, C Hug are employees of Vertex Pharmaceuticals and may hold stock and/or stock options in the company.

J Goldin reports ‘other’ conflicts – Founder of MedQIA during the conduct of the study.

F Ratjen reports grants and personal fees from Vertex Pharmaceuticals, personal consulting fees from Novartis, Bayer, Roche, Genetech, and Prosteostasis.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.